MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-06-28 EDT | ||
| 14.44 EUR | +1.26% |
|
| Current month | +16.52% | ||
| 1 month | +17.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 14.42 | +1.19% |
| 24-06-27 | 14.26 | -1.52% |
| 24-06-26 | 14.48 | -3.18% |
| 24-06-25 | 14.95 | +7.05% |
| 24-06-24 | 13.96 | -0.71% |
Real-time Euronext Paris
Last update June 28, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| AR9KB | |
| ISIN | FRBNPP05LJ03 |
| Date issued | 2023-04-17 |
| Strike | 470 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.66 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.13 € |
|---|---|
| Lowest since issue | 1.685 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- AR9KB Certificat
